About MEDINET
MEDINET is a publicly listed company based in Shinagawa (Japan) founded in 1995. Research support services for immune cell therapy are offered. It operates on a Professional Services and HealthTech model. The company has 112 employees. Its website medinet-inc.co.jp draws about 17 thousand monthly visits. MEDINET offers products and services including Immunotherapy Cell Processing, Specific Cell Product Manufacturing, Regenerative Medicine Product Manufacturing, Self-Cancer Tissue Bank, and Facility Operation Support. Its focus areas include Biotechnology and Regenerative Medicine. Its legal entity is MEDINET Co., Ltd.
Company details
MEDINET is involved in providing total solutions for regenerative and cell therapy. The company is focused on immunotherapy cell processing, specific cell product manufacturing, and regenerative medicine product development. Services are extended to facility operation support and self-cancer tissue banking. The healthcare sector is primarily targeted, with an emphasis on biotechnology and innovative medical treatments for cancer and other conditions.
- Headquarters Shinagawa, Japan
- Employees 112
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website medinet-inc.co.jp
- Legal Name Medinet Co., Ltd.
- Annual Revenue$5.48 M (USD)5.44as on Sep 30, 2025
- Net Profit-$9.19 M (USD)-6.67as on Sep 30, 2025
- EBITDA-$9.05 M (USD)-5.67as on Sep 30, 2025
- Investors
- Employee Count112
Products & Services of MEDINET
MEDINET offers a comprehensive portfolio of products and services, including Immunotherapy Cell Processing, Specific Cell Product Manufacturing, Regenerative Medicine Product Manufacturing, Self-Cancer Tissue Bank, and Facility Operation Support.
Cell processing for immunotherapy is provided to clients.
Manufacturing of specific cell products is undertaken for clients.
Regenerative medicine products are manufactured for clinical trials.
Cancer tissue storage is offered free for patients.
Support for cell processing facility operations is provided.
Funding Insights of MEDINET
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of MEDINET with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2015 | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in MEDINET
MEDINET has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Whiz Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management services are offered by Whiz Partners. | whizp.com |
Investor details for MEDINET
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of MEDINET
MEDINET is a publicly listed company on the TSE with ticker symbol 2370 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Oct 2003
- Listed onTSE: 2370
- Listed entityMEDINET Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3920990003
- Share price23.00 JPY · 2026-10-14
- Market capitalisation6,547,347,839.00 JPY
- EPS (diluted, trailing year)-4.06 JPY
- Volume (last session)254,400
Financials of MEDINET
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 810.3M JPY | -1.36B JPY | -1.34B JPY |
| 2024 | 768.5M JPY | -1.28B JPY | -1.27B JPY |
| 2023 | 661.5M JPY | -1.44B JPY | -1.35B JPY |
| 2022 | 633.7M JPY | -1.25B JPY | -1.25B JPY |
| 2021 | 683.0M JPY | -843.4M JPY | -960.8M JPY |
Detailed financial statements for MEDINET
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of MEDINET
3 dated milestones of MEDINET across 20 years, from founding to its latest funding, stage changes and deals.
- Founded MEDINET is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
Web traffic of MEDINET
The website of MEDINET (medinet-inc.co.jp) receives about 16.7K visits a month and ranks #1,570,145 among all websites worldwide, #2,092 in Biotechnology and Pharmaceuticals.
- Monthly visits16.7K
▲ 25.7% vs previous month
- Unique visitors5.7K
per month
- Global rank#1,570,145
among all websites
- Category rank#2,092
Health · Biotechnology and Pharmaceuticals
- Bounce rate50%
- Pages per visit2.8
- Average visit2 min 03 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with MEDINET. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
mdnt.co.jp | mdnt.co.jp | 100% | #3,058,356 | – | |
| medibic.com | 98% | 2.1K | #6,817,311 | View details | |
reprocell.co.jp | reprocell.co.jp | 91% | #1,008,625 | – | |
| google.com | 25% | 85.8B | #1 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medinet
Complete news archive for MEDINET
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MEDINET
MEDINET was founded in 1995 and raised its 1st funding round 20 years after it was founded.
MEDINET is headquartered in Shinagawa, Japan. It is registered at Shinagawa, Tokyo, Japan.
MEDINET has 112 employees.
Annual revenue of MEDINET is $5.48M as on Sep 30, 2025.
MEDINET is involved in providing total solutions for regenerative and cell therapy. The company is focused on immunotherapy cell processing, specific cell product manufacturing, and regenerative medicine product development. Services are extended to facility operation support and self-cancer tissue banking. The healthcare sector is primarily targeted, with an emphasis on biotechnology and innovative medical treatments for cancer and other conditions.
MEDINET offers Immunotherapy Cell Processing, Specific Cell Product Manufacturing, Regenerative Medicine Product Manufacturing, Self-Cancer Tissue Bank, and Facility Operation Support.
Yes, MEDINET is publicly traded on TSE under the ticker symbol 2370.
MEDINET has 1 investor. Key investors include Whiz Partners.
MEDINET operates through Medinet Co., Ltd..